SPOTLIGHT -
EP. 1: Accurately Diagnosing Mantle Cell Lymphoma
EP. 2: Treatment Approaches in Mantle Cell Lymphoma
EP. 3: Go-To Treatment Regimens in Mantle Cell Lymphoma
EP. 4: Lenalidomide and Bortezomib for Mantle Cell Lymphoma
EP. 5: BTK Inhibitors for Relapsed Mantle Cell Lymphoma
EP. 6: Acalabrutinib and Zanubrutinib for Relapsed MCL
EP. 7: Selecting a BTKi for Relapsed MCL Treatment
EP. 8: BTK Inhibitors for Relapsed MCL: Important Considerations
EP. 9: Venetoclax in Mantle Cell Lymphoma
EP. 10: CAR T-Cell Therapy for R/R Mantle Cell Lymphoma
EP. 11: Emerging BTK Inhibitors in Mantle Cell Lymphoma
EP. 12: MCL: Emerging BTKi-Combination Approaches
EP. 13: Novel Therapies in the Pipeline in Mantle Cell Lymphoma
EP. 14: MRD Assessment in Mantle Cell Lymphoma
EP. 15: Next Steps in Mantle Cell Lymphoma
Up-Front Osimertinib Provides Comparable OS, Improved Brain PFS Vs Sequential Gefitinib/Osimertinib in EGFR+ NSCLC
Dr Nasioudis on the Use of NGS to Identify the Molecular Profile of Endometroid Ovarian Cancer
Dr Buckingham on the Use of Patient-reported Outcomes to Predict Frailty in Patients With Ovarian Cancer
Dr Slomovitz on the Investigation of Letrozole Plus Ribociclib in Low-Grade Serous Ovarian Carcinoma
